Cancer Immunology – Multimedia

We are using single domain antibodies as innovative tools such as biosensors able to capture the conformation states of some membrane receptors such as EGFR or metabotropic glutamate receptors (mGluRs) on living cells.

In pursuit of lead structures, ‘omic technologies are revolutionizing the discovery and development of novel biological lead structures.

Immune checkpoint receptors are promising new immunotherapy
targets for the treatment of a variety of diseases including cancer and
autoimmune-mediated disorders. We developed a suite of cell-based
bioluminescent reporter bioassays for individual and combination
immune checkpoint immunotherapy targets including: PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT, GITR, 4-1BB, CD40, and OX40.

Graham Jones, Professor, Northeastern University, speaking at Flow Chemistry Congress.

A complementary cell analysis method has been developed to assess the dynamic interactions of tumor cells with resident tissue and immune cells using optical light scattering and impedance spectroscopy to shed light on tumor cell behavior.

Immunotherapy, also called biologic therapy or biotherapy, stimulates certain parts of the immune system to fight diseases such as cancer. Important drug targets in immunotherapy include: Co-inhibitory receptors, such as PD-1/PD-L1, CTLA-4, LAG3, Tim3; and co-stimulatory receptors, such as GITR, CD40, OX40, 4-1BB.
Current approaches to assaying these targets are cumbersome and variable. Here we offer an improved in vitro bioassay approach.

Peter Ertl discusses how for the first time, direct cell-to-cell interactions of tumor cells with bead-activated primary T cells were continuously assessed using an effector cell to target cell ratio of 10:1.

Aberrant sialylation affects the metastatic behaviour of cancer cells.We have quantified the sialylated cell surface glycoproteins from cells with different metastatic behaviour.The membrane proteins from isogenic human cell lines were analyzed by a method based on TiO2-HILIC-MS.1200 sialylated glycosites, 116 enzymes involved in the glycoconjugate metabolism and for the first time 4 glycosylation sites of Her2 receptor were identified, showing the importance of this tool for discovery and thera

Here we show specific cytotoxicity resulting from siRNA-induced silencing of EEF2, as well as specific delivery to PSMA-expressing prostate cancer cells. Increasing the valency of the aptamer resulted in enhanced cytotoxicity compared with the monovalent constructs. The results presented here demonstrate the usefulness of multivalent aptamer-based delivery vehicles for siRNA therapeutics.